12Nov/13

TG Therapeutics, Inc. (TGTX): TG Therapeutics' CEO Discusses Q3 2013 Results … – Seeking Alpha

TG Therapeutics, Inc. (TGTX): TG Therapeutics’ CEO Discusses Q3 2013 Results
Seeking Alpha
The third preclinical poster will demonstrate the activity of 1202 in Hodgkin’s lymphoma cell lines as a single agent as well as in combination with rituximab and anti-CD 30 conjugated monoclonal antibody approved for patients with Hodgkin’s lymphoma 

and more »

12Nov/13

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1 – Seeking Alpha

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1
Seeking Alpha
submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin’s lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.

and more »